Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Accumulated Expenses (2023 - 2024)

Tonix Pharmaceuticals Holding (TNXP) has 2 years of Accumulated Expenses data on record, last reported at $33000.0 in Q2 2024.

  • For Q2 2024, Accumulated Expenses changed N/A year-over-year to $33000.0; the TTM value through Jun 2024 reached $33000.0, changed N/A, while the annual FY2023 figure was $44000.0, N/A changed from the prior year.
  • Accumulated Expenses reached $33000.0 in Q2 2024 per TNXP's latest filing, down from $44000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $44000.0 in Q4 2023 and bottomed at $32000.0 in Q3 2023.